Addex Therapeutics arrives at its first-quarter 2026 report as a company that gave away its own future - deliberately. In April 2024 the Swiss clinical-stage developer sold its allosteric-modulator discovery platform and most of its early programs to a newly formed company, Neurosterix, for CHF 5 million and a 20% equity stake, sending almost all its employees along with it. The transaction was a restructuring of Addex into a lean holding vehicle: what it kept was a slice of the platform it just sold, a handful of partnered and residual CNS programs, and a permanently shrunken cost base. Two years later the arithmetic of that decision has come due. The first-quarter 2026 report, furnished in late June 2026, shows cash of CHF 0.9 million ($1.2 million) against a quarterly operating burn of roughly CHF 0.8 million ($1.0 million), and management says plainly that existing cash covers operations only through the end of July 2026. As of the report date, nothing on the company's public record since that disclosure reverses the countdown.
The quarter itself is small beer and intentionally so. Net loss was CHF 1.7 million ($2.2 million), barely larger than the year-ago CHF 1.5 million, because the machine that once burned tens of millions now operates with three full-time employees and outsourced research. The main driver of the loss is no longer Addex's own programs but the money-losing equity-method stake in Neurosterix - CHF 1.2 million of it in the quarter alone. That is the thesis in a sentence: Addex is now, in substance, a carry on a 20% position in the company that absorbed its pipeline, financed by a dwindling pile of cash. The stock trades near its 52-week low at about $5.95 per ADS, a roughly $6 million market capitalization that sits barely above the cash-and-investments on its balance sheet. The decisive question is not whether this quarter was good or bad; it is whether Addex can survive, or find a buyer for what it still holds, before the runway is tapped.
The company is a vehicle now, and vehicles price on survival. The central investment tension is between the residual value held inside Addex - a 20% stake in Neurosterix, the Indivior and Sinntaxis partnerships, the independent chronic-cough program - and the near-term certainty that those assets cannot be developed with CHF 0.9 million of cash. Every valuation that matters pivots on a financing or a monetization event, not on earnings, because there are effectively no earnings. What would confirm the thesis is a disclosed capital raise, a partner milestone, or a sale of the Neurosterix stake before cash is exhausted. What would break it is a going-concern disclosure with nothing behind it but time.